<a href="https://laohu8.com/S/CTOR">Citius Oncology</a> Announces Warrant and Share Issuance in $18 Million Offering
Citius Oncology Inc. has announced agreements involving the issuance of warrants and share rights as part of an $18 million concurrent registered direct offering and private placement. The company will issue unregistered warrants to purchase up to 1,284,404 shares of common stock at $1.09 per share in the registered direct offering, and additional warrants to purchase up to 15,229,358 shares of common stock at $1.09 per share in a private placement. The exercise of these warrants is contingent on stockholder approval and they will expire five years from the date of such approval. Additionally, Citius Oncology will amend previously issued warrants, reducing their exercise price to $1.09 per share, effective upon closing of the offerings. Proceeds will support the commercial launch of LYMPHIR™, a cancer immunotherapy for cutaneous T-cell lymphoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-120197), on December 10, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。